Title of the cohort
Cohort – KNDD-LANDSCAPE
Acronym for cohort
LANDSCAPE
Name of Principal Investigator
| Title | Prof. Dr. |
| First name | Richard |
| Last name | Dodel |
Address of institution where award is held
| Institution | Dept. of Neurology, University Marburg |
| Street Address | Rudolf-Bultmann-Str. 8 |
| City | Marburg |
| Postcode | 35039 |
Country
Germany
Website
http://www.therapieforschung-neurologie.eu
Contact email
Funding source
1. The cohort includes, or expects to include, incidence of the following conditions
- Alzheimer’s disease and other dementias
- Parkinson’s disease
When studies on the above condition(s) are expected to become possible
2011 – 2015
2a. Stated aim of the cohort
To investigate the development of and risk factors of dementia in patients with Parkinson’s disease and Lewy body dementia
2b. Features distinguishing this cohort from other population cohorts
3a. i) Number of publications that involve use of cohort to date
0
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)
3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment
| Age in years from: | 45 |
| To (‘until death’ if applicable): | 80 |
4b. Study criteria: inclusion criteria
Parkinson’s disease; Parkinson’s disease and dementia; Parkinson’s disease with MCI; Lewy body dementia
4c. Study criteria: exclusion criteria
Other dementias
5. Size of the cohort (i.e. number of participants enrolled)
1,000 – 5,000 participants
6a. Measures used to characterise participants
Detailed neuropsychometric testing; UPDRS; clinical examination; cMRI
6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)
No
7. Study design
- Prospective cohort
- Longitudinal
8. Cases matched by
- Age
- Cognitive function
- Physical ability
9a. Does the study include a specialised subset of control participants
Yes
9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date
01-01-2010
10a. ii) Data collection end date
10a iii) Data collection for this study is
- Data collection ongoing
- Data analysis ongoing
10b. Plans to continue the cohort study beyond the current projected end date
11. Data collected
12. System in place to enable re-contact with patients for future studies
13a. Format and availability of data stored in a database
Language used:
13b. Format and availability of data held as individual records
Language used:
14a. Are data available to other groups
Yes
14b. Access policy/mechanisms for access if data are available to other groups
15. Data sharing policy specified as a condition of use
Data to be made publicly available immediately
16a. Are tissues/samples/DNA available to other groups
Yes
16b. i) Description of available tissues/samples/DNA
16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
17. Is information on biological characteristics available to other groups
- Yes, for all the cohort